HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Faces Potential High Penalties Under SEC Deal; Q3 Sales Down 7%

This article was originally published in The Rose Sheet

Executive Summary

Avon says the impact of a settlement with the U.S. Securities and Exchange Commission and Department of Justice to resolve investigations into its foreign business practices in recent years could be significantly greater than planned for. Meanwhile, the firm works to rebuild its direct-sales platforms in North America, where declines in field representatives have created a drag on revenue.

You may also be interested in...



Avon Settlement With Feds Over Bribery Charges Could Reach $132 Mil.

Firm is optimistic that an end to negotiations with federal agencies regarding alleged misconduct in China could be on the horizon. However, the firm’s sales continue to suffer as the firm labors to right its business.

Avon Must Focus On Markets Abroad To Emerge From “Abyss” – Analysts

While the U.S. is still integral to Avon’s business, analysts believe that focusing on markets outside of the firm’s home country will be what brings about a turnaround for the direct seller.

Avon Clearing the Decks: Firm Ousts Cramb Amid Ongoing Investigation

Avon announces dismissal of Vice Chairman Charles Cramb in connection with firm’s internal investigation into possible breach of fiduciary duty and alleged violations of the Foreign Corrupt Practices Act. With CEO Andrea Jung on her way out as well, analysts see in the decay of Avon’s upper management glimmers of opportunity.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel